Werewolf Therapeutics
HOWL
70 hedge funds and large institutions have $26.7M invested in Werewolf Therapeutics in 2025 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 19 reducing their positions, and 9 closing their positions.
26% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 19
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2.01% less ownership
Funds ownership: 63.24% → 61.22% (-2%)
4% less funds holding
Funds holding: 73 → 70 (-3)
33% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 9
36% less capital invested
Capital invested by funds: $41.7M → $26.7M (-$15M)
72% less call options, than puts
Call options by funds: $7K | Put options by funds: $25K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$247K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$116K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$107K |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$45.8K |
| 5 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$33.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$522K |
| 2 |
BC
BIT Capital
Berlin,
Germany
|
-$357K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$144K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$91.7K |
| 5 |
Two Sigma Advisers
New York
|
-$81.3K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
D.E. Shaw & Co
New York
| – | -$26.3K | -17,776 | Closed |
|
77
SG Americas Securities
New York
| – | -$20K | -13,779 | Closed |
|
|
TSS
78
Two Sigma Securities
New York
| – | -$18.9K | -12,740 | Closed |
|
79
Nisa Investment Advisors
St. Louis,
Missouri
| – | -$59 | -40 | Closed |
|
HOWL Hedge Fund Activity: Q1 2025 in Review
70 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Werewolf Therapeutics (HOWL) for Q1 2025, worth a combined $26.7M — down 36% from $41.7M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of HOWL and 6 opened new positions — a net loss of 3 holders — while 19 trimmed existing stakes and 24 added.
The largest buyer was Millennium Management, adding an estimated $247K. The largest seller was PFM Health Sciences, cutting an estimated $522K.
- 70 institutional investors held Werewolf Therapeutics (HOWL) as of Q1 2025, down from 73 in Q4 2024.
- Funds reported $26.7M of Werewolf Therapeutics stock for Q1 2025, down 36% quarter-over-quarter.
- 6 funds opened new Werewolf Therapeutics positions in Q1 2025 and 9 closed out, a net change of -3 holders.
- The largest Werewolf Therapeutics buyer in Q1 2025 was Millennium Management, an estimated $247K added.
- The largest Werewolf Therapeutics seller in Q1 2025 was PFM Health Sciences, an estimated $522K sold.
Based on aggregated 13F filings for Q1 2025.